Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Affymax, Inc.
Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Affymax, Inc. Business Wire LOS ANGELES -- April 6, 2013 Glancy Binkow & Goldberg LLP announces that purchasers of the securities of Affymax, Inc. (“Affymax” or the “Company”) (NASDAQ:AFFY) between December 8, 2011 and February 22, 2013, inclusive (the “Class Period”), have until April 29, 2013 to file a motion with the Court to be appointed as lead plaintiff. The shareholder lawsuit was filed in the United States District Court for the Northern District of California. The Complaint alleges that throughout the Class Period the Company and certain of its executive officers issued materially false and misleading statements regarding the Company’s business and financial prospects. Affymax is a biopharmaceutical company engaged in the development of drugs in the United States for the treatment of serious and life-threatening conditions. On February 23, 2013 Affymax and Japan-based Takeda Pharmaceutical Company Limited (Takeda) issued a joint announcement of a nationwide voluntary recall of OMONTYS (peginesatide) Injection. OMONTYS Injection is a treatment for anemia due to chronic kidney disease in adult patients on dialysis. Affymax has a strategic alliance agreement with Takeda to develop and commercialize OMONTYS. According to the Company, the recall is related to “new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal.” The Complaint alleges that defendants failed to disclose that 0.02% of patients who were administered OMONTYS experienced fatal anaphylaxis reactions. As a result of this false statement, Affymax stock traded at artificially inflated prices during the Class Period. If you purchased Affymax shares during the Class Period, you have until April 29, 2013 to move the Court to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class you need not take action at this time; you may retain counsel of your choice or take no action and remain an absent Class member. To learn more about this action, or if you have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by telephone at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact: Glancy Binkow & Goldberg LLP, Los Angeles, CA Michael Goldberg (310) 201-9150 or (888) 773-9224 email@example.com www.glancylaw.com